The Food and Drug Administration’s independent panel of advisors on Wednesday recommended GlaxoSmithKline’s
 RSV vaccine for adults ages 60 and older, though they flagged potential safety issues over nervous system disorders that may be tied to the shot.

Reuters

United Kingdom

GSK catches up with Pfizer in RSV vaccine race after FDA panel's backing

A panel of outside advisers to the U.S. health regulator on Wednesday backed GSK Plc's respiratory syncytial virus (RSV) vaccine, setting it up for a race with rival Pfizer to become the first approved U.S. shot against the disease.

Ad Fontes Media

All Sides

Media Bias/Fact Check

The Woodbridge Company

The vaccines still face several regulatory hurdles before approval. If that happens, the vaccines will likely become available by the next RSV season.

USA Today

Gannett

United States

FDA experts recommend RSV vaccines for adults 60 and over. What's next?

A majority of the FDA panel said GSK's vaccine safety data was adequate, and the advisors were unanimous that the shot's efficacy was good.

CNBC

Roberts family

FDA advisors recommend GSK's RSV vaccine for older adults, but flag potential safety risks

A Food and Drug Administration (FDA) advisory panel on Wednesday recommended the second vaccine for respiratory syncytial virus (RSV) in older adults in as many days, setting up a race between manufacturers looking to bring the first-of-its-kind shot to market. The 12-member panel voted 10-2 that the vaccine developed by GlaxoSmithKline is safe and separately…

The Hill

Nexstar Media Group

Washington

District of Columbia

FDA advisers back GlaxoSmithKline RSV vaccine for older adults

The Food and Drug Administration's vaccine advisory committee has recommended GlaxoSmithKline’s and Pfizer's respiratory syncytial virus vaccine candidates for older adults, paving the way for approval of the country's first RSV vaccine.

Washington Examiner

Philip Anschutz

FDA vaccine advisers back safety of RSV vaccines for older adults

A committee of outside advisers to the U.S. Food and Drug Administration (FDA) recommended a vaccine from GlaxoSmithKline (GSK) against the respiratory syncytial virus (RSV) for adults over age 60.
The vote from the Vaccines and Related Biological Products Advisory Committee (VRBPAC) for GSK’s Arexvy (RSVPreF3-AS01) vaccine comes a day after the 12 members voted to endorse Pfizer’s vaccine candidate, Abrysvo (RSVPreF), for the same age group.
Fo…

The Epoch Times

Epoch Media Group

New York

FDA Panel Endorses GSK Vaccine for RSV in Older Adults, a Day After Recommending Pfizer's Vaccine

Over the course of a two-day meeting, vaccine advisers to the FDA voted in favor of approval for RSV vaccines for adults over the age of 60.

abc 6 Philadelphia

The Walt Disney Company

Philadelphia

Philadelphia County

Pennsylvania

RSV vaccine: FDA advisers vote in favor of approval for vaccines for older adults

FDA advisors recommend GSK's RSV vaccine for older adults, but flag potential safety risks

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics